Tarceva is approved for:
Maintenance Therapy and Second- or Third-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC):
Tarceva is prescribed for patients with advanced-stage NSCLC whose cancer has not spread or grown after initial treatment with certain types of chemotherapy (maintenance treatment).
Tarceva is prescribed for patients with advanced-stage NSCLC whose cancer has spread or grown after receiving at least 1 chemotherapy regimen (2nd/3rd-line treatment).
Tarceva is not meant to be used at the same time as certain types of chemotherapy for advanced NSCLC.